Oxypurinol (XRX-OXY)
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Key Facts
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase
Phase 3
Status
Active - Pivotal Trial
Company
About XORTX Therapeutics
XORTX Therapeutics is a clinical-stage biotech focused on developing treatments for progressive kidney diseases driven by elevated uric acid. Its core achievement is advancing oxypurinol, a xanthine oxidase inhibitor, into a pivotal Phase 3 trial (XRX-OXY-301) for ADPKD, a condition with no approved disease-modifying therapies. The company's strategy leverages established drug safety to de-risk development while targeting a significant unmet medical need. Success in its Phase 3 trial would validate its scientific hypothesis and create substantial value.
View full company profileTherapeutic Areas
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| Small Molecule Potentiator Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| PDE4 Allosteric Modulator Program | Mironid | Pre-clinical |
| Tolvaptan | Otsuka Holdings | Approved |
| PXL-770 | Scynexis | Phase 2-ready |